Holen Sie sich die Stockscreener-App
39.39
1.82%
-0.73
Handel nachbörslich:
39.39
Schlusskurs vom Vortag:
$40.12
Offen:
$40.11
24-Stunden-Volumen:
504.49K
Relative Volume:
0.77
Marktkapitalisierung:
$2.21B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-146.66M
KGV:
-14.30
EPS:
-2.7541
Netto-Cashflow:
$-133.21M
1W Leistung:
+4.23%
1M Leistung:
+21.88%
6M Leistung:
-32.42%
1J Leistung:
-27.31%
1-Tages-Spanne:
$38.86
$40.15
1-Wochen-Bereich:
$36.59
$41.05
52-Wochen-Spanne:
$26.20
$63.50
Apogee Therapeutics Inc Stock (APGE) Company Profile
Firmenname
Apogee Therapeutics Inc
Sektor
Branche
Telefon
650-394-5230
Adresse
221 CRESCENT ST., WALTHAM
Vergleichen Sie APGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
39.39 | 2.21B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-11-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-10 | Eingeleitet | BofA Securities | Buy |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | Guggenheim | Buy |
| 2023-08-08 | Eingeleitet | Jefferies | Buy |
| 2023-08-08 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade - Yahoo Finance
Apogee Therapeutics, Inc. (NASDAQ:APGE) Holdings Lowered by Invesco Ltd. - Defense World
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference - The Manila Times
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference - GlobeNewswire Inc.
Wells Fargo & Company MN Lowers Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
JPMorgan Chase & Co. Has $1.69 Million Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
It would be worthwhile to take a closer look at Apogee Therapeutics Inc (APGE) - uspostnews.com
Companies Like Apogee Therapeutics (NASDAQ:APGE) Are In A Position To Invest In Growth - Yahoo Finance
First Week of APGE June 20th Options Trading - Nasdaq
When (APGE) Moves Investors should Listen - news.stocktradersdaily.com
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Geode Capital Management LLC Has $36.98 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics: Engineering Biologic Dominance (NASDAQ:APGE) - Seeking Alpha
Vanguard Group Inc. Sells 29,445 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Commonwealth Equity Services LLC Buys Shares of 4,906 Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
KLP Kapitalforvaltning AS Acquires New Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Insider Purchases Worth US$990.8k See Losses As Apogee Therapeutics Market Value Drops To US$1.9b - simplywall.st
Corebridge Financial Inc. Cuts Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics’ chief medical officer sells $139,801 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics’ chief medical officer sells $139,801 in stock - Investing.com Australia
Teacher Retirement System of Texas Purchases 1,848 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Swiss National Bank Raises Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $92.17 - The AM Reporter
Analysts Set Apogee Therapeutics, Inc. (NASDAQ:APGE) PT at $92.17 - Defense World
Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025? - Insider Monkey
(APGE) Trading Advice - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Sells 2,936 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
12 Best IPO Stocks to Buy in 2025 - Insider Monkey
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Bank of New York Mellon Corp Decreases Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
May 16th Options Now Available For Apogee Therapeutics (APGE) - Nasdaq
(APGE) Trading Signals - Stock Traders Daily
Apogee Therapeutics (NASDAQ:APGE) Coverage Initiated at Citigroup - Defense World
Victory Capital Management Inc. Sells 123,296 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics (NASDAQ:APGE) Trading Up 4.5%What's Next? - MarketBeat
Citigroup Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - Nasdaq
Citigroup Initiates Apogee Therapeutics at Buy With $95 Price Target -March 13, 2025 at 07:14 am EDT - Marketscreener.com
Apogee Therapeutics initiated with a Buy at Citi - TipRanks
Zevra Therapeutics Inc (ZVRA) gets rating Resumed from Cantor Fitzgerald - Knox Daily
Apogee Therapeutics (NASDAQ:APGE) Given Outperform Rating at Wedbush - Defense World
Apogee Therapeutics signs manufacturing deal with Samsung Biologics By Investing.com - Investing.com Canada
Apogee Therapeutics signs manufacturing deal with Samsung Biologics - Investing.com India
Apogee Therapeutics IncEnters Master Services Agreement With Samsung Biologics - Marketscreener.com
TD Cowen reiterates buy on Apogee Therapeutics stock - Investing.com India
TD Cowen reiterates buy on Apogee Therapeutics stock By Investing.com - Investing.com UK
Strong Buy Recommendation for Apogee Therapeutics Driven by Promising Clinical Data and Strategic Pipeline Developments - TipRanks
Finanzdaten der Apogee Therapeutics Inc-Aktie (APGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):